Ces Urol 2017, 21(4):284-288 | DOI: 10.48095/cccu2017041
Experience with the prostate health index in daily clinical practice
- Urologická klinika VFN a 1. LF UK v Praze
Fiala V, Sobotka R, Vaľová Z, Pešl M, Hradec T, Hanuš T, Čapoun O. Experience with the prostate health index in daily clinical practice.
Aim: The use of prostate health index (PHI) for prostate cancer (PCa) diagnosis in patients with elevated prostate-specific antigen (PSA) level.
Methods: Between 05/2015 and 05/2016 we performed 230 PHI examinations. We recorded age, PSA and free to total PSA ratio (f/tPSA) before the indication of PHI, PSA, f/tPSA and [-2]proPSA level measured in PHI calculation, size of the prostate, digital rectal examination finding and histology result in case of a prostate biopsy (PB). The distribution of parameters in different groups and subgroups was assessed by nonparametric tests and their correlation by Spearman's correlation coefficient.
Results: Median of age was 66 years (60-71). Median PSA level before indication of PHI was 6.1 ng/ml (4.1-9.4). Median of phi was 34.9 (26.7-48.2). Median prostate size was 40 ml (28-60 ml). Information about follow up after PHI measurement was available in 217 (94.4 %) patients until 01/2017. Repeated examination of PSA or phi only was indicated in 134 (61.8 %) cases. Prostate biopsy was indicated in 71 (32.7 %) men and cancer was found in 23 (32.4 %) patients. Only the phi result was not related to the size of prostate (p=0.4708). From laboratory parameters were significant for prediction of PB only fPSA/PSA ratio measured before phi count (p=0.0217) and phi density (0.0209). The phi result was significantly higher in patients indicated to PB (mean 71.3 vs. 29.6; p=0.001) Conclusion: The use of PHI in daily clinical practice improves indication of rebiopsy. PHI to prostate size ratio is the best predictor of PCa diagnosis in rebiopsy.
Keywords: Clinical practice, prostate biopsy, prostate cancer, prostate health index, prostate specific antigen.
Received: August 31, 2017; Accepted: November 14, 2017; Published: December 19, 2017
References
- Mužík J, Dušek L, Babjuk M, et al. Uroweb - webový portál pro analýzu a vizualizaci epidemiologie, diagnostiky a léčby urologických malignit [online]. Masarykova univerzita, Brno, 2017. (Přístup 9. 8. 2017). Dostupný z WWW: http://www.uroweb.cz. ISSN 1804-6371. Verze 1.6d.
- Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 2009; 9: 14.
Go to original source... 
Go to PubMed... - Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate‑specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19): 1542-1547. Go to original source...
- Mikolajczyk S, Millar L, Wang T, et al. A precursor form of prostate‑specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60: 756-759.
- Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro‑prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185(5): 1650-1655. Go to original source... Go to PubMed...
- Čapoun O, Sobotka R, Soukup V, et al. Prostate health index (phi) in primary diagnosis of prostate cancer. Eur Urol Suppl 2014; 13(6) e1222. Go to original source...
- Fuchsová R, Topolčan O, Vrzalová J, et al. Přínos stanovení [-2]proPSA v diferenciální diagnostice karcinomu prostaty. Ces Urol 2014; 18(1): 21-25.
- Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate‑specific antigen in a community‑based population of healthy men. Establishment of age‑specific reference ranges. JAMA 1993 Aug 18; 270(7): 860-864. Go to original source...